Enalaprilat Anhydrous

Summary

Enalaprilat Anhydrous (CHEMBL577) is an approved small-molecule EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor targeting ACE.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 1 (ACE)
• Clinical trials: 3
• Chemistry: 348.4 Da · C18H24N2O5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL577
Name	Enalaprilat Anhydrous
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	44307141
ChEBI	CHEBI:4786
Molecular formula	C18H24N2O5
Molecular weight	348.4
InChIKey	LZFZMUMEGBBDTC-ZALBZXLWSA-N

SMILES: CC(C(=O)N1CCC[C@H]1C(=O)O)NC(CCC2=CC=CC=C2)C(=O)O

IUPAC name: (2S)-1-[2-[(1-carboxy-3-phenylpropyl)amino]propanoyl]pyrrolidine-2-carboxylic acid

ChEBI definition: Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.

Pharmacological roles (ChEBI): EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, antihypertensive agent.

Also known as: Enalaprilat anhydrous, enalaprilat, Enalaprilat, ENALAPRILAT, EnalaprilatÊ, EnalaprilatÂ, C0164805, ENALAPRILAT ANHYDROUS

Parent form; salt/anhydrous children: CHEMBL3989406

Patent coverage: 2,634 distinct patent families (10,256 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
ACE	Angiotensin-converting enzyme	Inhibition	7.5	0.7%	P12821

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Angiotensin-converting enzyme, Angiotensin-converting enzyme 2, Angiotensin-converting enzyme, Angiotensin-converting enzyme, Angiotensin-converting enzyme.

Bioactivity

ChEMBL activities: 25 potent at pChembl ≥ 5 of 25 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
Q5EGZ1	9.3	Ki	0.5	nM	CHEMBL_ACT_1274480
P47820	9.02	IC50	0.95	nM	CHEMBL_ACT_1114843
ACE	8.92	IC50	1.2	nM	CHEMBL_ACT_104318
ACE	8.92	IC50	1.2	nM	CHEMBL_ACT_25090607
ACE	8.92	IC50	1.2	nM	CHEMBL_ACT_313843
ACE	8.92	IC50	1.2	nM	CHEMBL_ACT_472509
ACE	8.92	IC50	1.2	nM	CHEMBL_ACT_509302
P12822	8.92	IC50	1.2	nM	CHEMBL_ACT_536679
ACE	8.92	IC50	1.2	nM	CHEMBL_ACT_919483
P12822	8.85	Ki	1.4	nM	CHEMBL_ACT_693009
P47820	8.64	IC50	2.3	nM	CHEMBL_ACT_270200
ACE	8.62	IC50	2.4	nM	CHEMBL_ACT_360943
ACE	8.6	IC50	2.5	nM	CHEMBL_ACT_18097732
ACE	8.59	IC50	2.6	nM	CHEMBL_ACT_343794
ACE	8.54	IC50	2.9	nM	CHEMBL_ACT_862484
ACE	8.4	IC50	3.98	nM	CHEMBL_ACT_528716
P47820	8.4	IC50	4	nM	CHEMBL_ACT_693003
P12822	8.37	IC50	4.3	nM	CHEMBL_ACT_544864
P12822	8.24	IC50	5.7	nM	CHEMBL_ACT_1016964
P12822	8.24	IC50	5.7	nM	CHEMBL_ACT_456627
P12822	8.24	IC50	5.8	nM	CHEMBL_ACT_509301
P12822	8.06	IC50	8.8	nM	CHEMBL_ACT_704361
P47820	8.02	IC50	9.6	nM	CHEMBL_ACT_18097720
P09470	7.94	IC50	11.5	nM	CHEMBL_ACT_18097726
ACE	5.51	IC50	3100	nM	CHEMBL_ACT_739478

Target pathways

Aggregated over 1 target gene(s): ACE.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Metabolism of Angiotensinogen to Angiotensins	1	ACE
Peptide hormone metabolism	1	ACE
Metabolism of proteins	1	ACE

Dominant GO biological processes

GO term	Targets
kidney development	1
blood vessel remodeling	1
angiotensin maturation	1
regulation of renal output by angiotensin	1
neutrophil mediated immunity	1
antigen processing and presentation of peptide antigen via MHC class I	1
regulation of systemic arterial blood pressure by renin-angiotensin	1
positive regulation of systemic arterial blood pressure	1
proteolysis	1
spermatogenesis	1
regulation of blood pressure	1
male gonad development	1
post-transcriptional regulation of gene expression	1
negative regulation of gene expression	1
substance P catabolic process	1

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02639637	PHASE4	COMPLETED	Effect of DPP4 Inhibition on Vasoconstriction
NCT00741156	PHASE3	COMPLETED	The Acute Effects of the Angiotensin-converting Enzyme Inhibitor Enalaprilat on Flow Distribution
NCT00226096	Not specified	COMPLETED	Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

32 molecules share ≥1 primary target. Top 32 by shared-target count:

Molecule	Source	Status	Shared targets
CAPTOPRIL	ChEMBL + PubChem	Phase 4 (approved)	ACE
LOSARTAN	ChEMBL + PubChem	Phase 4 (approved)	ACE
PERINDOPRIL	ChEMBL + PubChem	Phase 4 (approved)	ACE
SITAGLIPTIN	ChEMBL + PubChem	Phase 4 (approved)	ACE
BENAZEPRIL	ChEMBL	Phase 4 (approved)	ACE
ENALAPRIL	ChEMBL	Phase 4 (approved)	ACE
FOSINOPRIL	ChEMBL	Phase 4 (approved)	ACE
IMIDAPRIL	ChEMBL	Phase 4 (approved)	ACE
LISINOPRIL	ChEMBL	Phase 4 (approved)	ACE
MOEXIPRIL	ChEMBL	Phase 4 (approved)	ACE
QUINAPRIL	ChEMBL	Phase 4 (approved)	ACE
RAMIPRIL	ChEMBL	Phase 4 (approved)	ACE
TELMISARTAN	ChEMBL	Phase 4 (approved)	ACE
TRANDOLAPRIL	ChEMBL	Phase 4 (approved)	ACE
EDETIC ACID	ChEMBL	Phase 3	ACE
QUINAPRILAT	ChEMBL + PubChem	Phase 2 (approved)	ACE
BENAZEPRILAT	ChEMBL	Phase 2	ACE
CERONAPRIL	ChEMBL	Phase 2	ACE
FOSINOPRILAT	ChEMBL	Phase 2	ACE
IMIDAPRILAT	ChEMBL	Phase 2	ACE
LIBENZAPRIL	ChEMBL	Phase 2	ACE
MOEXIPRILAT	ChEMBL	Phase 2	ACE
OMAPATRILAT	ChEMBL	Phase 2	ACE
PROLINE	ChEMBL	Phase 2	ACE
RENTIAPRIL	ChEMBL	Phase 2	ACE
SAMPATRILAT	ChEMBL	Phase 2	ACE
SPIRAPRILAT	ChEMBL	Phase 2	ACE
TEPROTIDE	ChEMBL	Phase 2	ACE
ZOFENOPRIL	ChEMBL	Phase 2	ACE
Gallic Acid	PubChem	Approved	ACE
Hydrochlorothiazide	PubChem	Approved	ACE
Paclitaxel	PubChem	Approved	ACE